Innovative Healthcare 2013. Cancer: from Cause to Cure
Science Capital offer discounted rates to Lunar Society Members
Wednesday 25 September from 5:30-10pm at the Binding Site, 8 Calthorpe Rd Birmingham, B15 1QT
Website: www.sciencecapital.co.uk/2013-biomedical Organiser: Science Capital
This event is offered in partnership with The Lunar Society, and gives participants the opportunity to discuss the latest developments in drug discovery and cancer research and to build new connections at a time when open innovation, collaboration and partnership are increasing vital for development of new therapies. We will focus on exploring how academics, clinicians, biotech and pharmaceutical companies can work together and explore new opportunities for moving the field forwards in the region and beyond. Tickets cost £39 (Academic/SME) and include reception, dinner, panel discussion, and networking session.
Malcolm Skingle, Director, Academic European Liaison atGlaxoSmithKline, on how to compete on the international stage through collaboration. Malcolm is a passionate advocate for forming strong collaborations with the academic sector, and was awarded an Honorary Doctorate from the University of Birmingham and a Commander of the British Empire in the Queen’s Birthday honours list for services to the pharmaceutical industry.
Sanj Kumar, Sr. Vice President and General Manager at DiscoveRx, on taking new technologies from inception to market. His experience in the life sciences spans setting up operations for Pharmacia Biotech, bringing Biacore technology to market, and growing the European reach of DiscoveRx, which develops assays to accelerate drug discovery research.
Jo Morris will speak about her research on breast cancer genetics, including the predisposition gene BRCA1. She is a Senior Lecturer at the School of Cancer Sciences at the University of Birmingham, where she leads the Cancer Predisposition Pathways Laboratory. Her lab was recently awarded ‘Research Team of the Year’ by the Breast Cancer Campaign Breast Cancer.
Andy Pitt, Professor in Pharmaceutical Chemistry & Chemical Biology atAston University, former Director of the Sir Henry Wellcome Functional Genomics Facility at the University of Glasgow, and developer of the Molecular Nose. He will present on how targets are identified and how therapies are validated by post genomic technologies that map changes in genes, proteins and metabolites during disease progression and intervention.
Peter Sadler, Professor in Chemistry at the University of Warwick, on “Innovative Precious Metal Cancer Therapy”. Peter is a Fellow of the Royal Society of Edinburgh and the Royal Society of London, and focuses on the chemistry of metals in medicine, interactions with RNA, DNA and proteins, the design of novel therapeutic agents, and industrial and international interdisciplinary collaborations.
Participants are welcome to pitch their business plans and ideas to a panel of advisors in the afternoon. Selected legal, business, financial and investment advisors who are experienced in developing commercialisation strategies will provide friendly and supportive advice.
Pro-bono support is available to presenters from firms including FD Solutions, Quarto Perspective, Wragge & Co and Marks & Clerk.
Lunar Society members are entitled to a 20% discount, please contact Kate or Michael for the promotional code.